

ORIGINAL ARTICLE

Joanna M. Watson · David G.I. Kingston
Mahendra D. Chordia · Ashok G. Chaudhary
Clifford A. Rinehart · J. Stephen Haskill

Identification of the structural region of taxol that may be responsible for cytokine gene induction and cytotoxicity in human ovarian cancer cells

Received: 22 May 1997 / Accepted: 10 September 1997

Abstract Purpose: Interleukin-8 (IL-8) is a pleiotropic chemokine with both chemoattractant and angiogenic properties. In addition to its cytotoxic effects on ovarian cancer cells, taxol can transcriptionally activate genes such as IL-8 that may play a role in tumorigenesis. Utilizing IL-8 as a prototypic marker of tumor-derived modulators of growth, we undertook a systematic study of taxol and 11 structurally modified taxol analogs to identify the region of the taxane skeleton responsible for IL-8 gene induction. **Methods:** The human ovarian cancer cell line OVCA-420 was exposed to taxol or taxol analogs. IL-8 gene induction was assessed by Northern blot analysis after 6 h and cytotoxicity after 72 h. **Results:** Changes in the southern hemisphere (C-1 to C-4) of the taxane skeleton had greater effects on IL-8 induction than changes in the northern hemisphere (C-7 to C-11). Some of the taxol analogs modified at positions C-1 and/or C-2 with increased hydrophobicity induced IL-8 expression more than threefold over that

induced by taxol or taxotere and more than 20-fold over control cells. Cells that failed to induce IL-8 gene expression in response to taxol were only marginally responsive to the analogs unless first primed with IL-1 β . Modifications to the northern hemisphere did not alter taxol's effect on IL-8 expression in human cells, but did influence TNF α expression in murine macrophage cells, suggesting species and/or gene specificity. We found a direct correlation between IL-8 induction and cytotoxicity, in that analogs that dramatically upregulated IL-8 expression proved to be the most cytotoxic, inhibiting cell survival by >90%. **Conclusion:** Taken together our results demonstrate that changes in the southern hemisphere of the taxane skeleton influence both the gene induction and cytotoxic potential of taxol in human ovarian cancer cells.

Key words Taxol · Analogs · Gene induction · IL-8 · Human ovarian cancer · Cytotoxicity

Abbreviations IL-8 interleukin 8 · TNF α tumor necrosis factor α · DMSO dimethylsulfoxide · LPS lipopolysaccharide · MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide:thiazole blue)

J.M. Watson
Lineberger Comprehensive Cancer Center, The University
of North Carolina, Chapel Hill, NC 27599-7295, USA

C.A. Rinehart
Department Pathology and Laboratory Medicine,
The University of North Carolina,
Chapel Hill, NC 27599-7295, USA

J.S. Haskill
Department of Obstetrics and Gynecology, The University
of North Carolina, Chapel Hill, NC 27599-7295, USA

J.S. Haskill
Department of Microbiology and Immunology, The University
of North Carolina, Chapel Hill, NC 27599-7295, USA

D.G.I. Kingston · M.D. Chordia · A.G. Chaudhary
Department of Chemistry, Virginia Polytechnic Institute
and State University, Blacksburg, VA 24061-0212, USA

J.S. Haskill (✉)
UNC Lineberger Cancer Center, CB #7295 Rm. 214,
The University of North Carolina, Chapel Hill,
NC 27599-7295, USA
Tel.: +1-919-966-3098; Fax: +1-919-966-3015

Introduction

Interleukin-8 (IL-8) is a pleiotropic chemokine originally identified as a potent chemoattractant [1]. In addition to its chemoattractant properties, IL-8 can modulate adhesion receptors and adhesive interactions between neutrophils and endothelial cells [2]. Many diverse cell types produce IL-8 either constitutively or in response to proinflammatory stimuli [1]. IL-8 can function as a tumor modulator since it is produced constitutively by some colon cancer cell lines and melanoma cells [3–5], functioning as an autocrine growth factor [4]. IL-8 expression correlates directly with tumorigenicity and metastatic potential in vivo [4, 5] possibly reflecting IL-8-induced angiogenesis [6, 7].

Taxol is one of the few recent chemotherapeutic drugs that has improved the progression-free interval for human ovarian cancer patients with advanced disease [8]. The *in vivo* efficacy of taxol is greater than that of other antimitotic agents suggesting that mitotic inhibition is not solely responsible for its clinical response. This has led investigators to pursue other mechanisms of action for taxol. One such mechanism may be through the induction of cytokines via signal transduction pathways. Recently taxol has been shown to transcriptionally activate IL-8 gene expression in a subset of human ovarian cancer cell lines and to increase IL-8 secretion from several primary cultures of ovarian tumors [9]. Gately et al. have also demonstrated taxol-induced transcriptional activation of the GADD153 promoter in ovarian cancer cells [10]. Taxol alters a wide variety of regulatory activities including activation of microtubule-associated protein kinase, induction of protein-tyrosine phosphorylation, tumor necrosis factor (TNF) and IL-1, modulation of TNF receptor levels in murine macrophages [11, 12], augmentation of LPS-induced pro-IL-1 β production, and inhibition of colchicine-induced IL-1 α secretion in human monocytes [13, 14]. Additionally, taxol activates mitogen-activated protein (MAP) kinase and induces expression of the cell cycle regulatory protein p21, through the *c-raf*-1 pathway in both MCF-7 breast cancer cells and PC3M human prostate cancer cells [15].

Taxol (Fig. 1A) is a natural product derived from the bark of the Pacific Northwest Yew tree, *Taxus brevifolia* [16]. A number of taxane compounds have been isolated from other *Taxus* species, most notably the taxotere precursor, 10-deacetyl baccatin III, from the needles of *Taxus baccata* [17]. Some of these taxanes are as potent as taxol, exhibiting comparable cytotoxicity and microtubule stabilization properties [11, 18, 19]. Little is known about the structural elements of the taxol molecule that are required for gene induction although modifications to the northern hemisphere of taxol have been shown to influence TNF gene induction in murine macrophages [11]. Using IL-8 as a prototypic marker for tumor-derived modulators of growth induced by taxol, we evaluated a series of taxol analogs modified at different positions on the taxane ring skeleton to identify the region of the molecule responsible for IL-8 gene induction in the human ovarian cancer cell lines OVCA 420 and 429. We found that some analogs modified at positions C-1 and C-2 resulting in a loss of polarity, dramatically enhanced IL-8 gene induction and that this had a direct correlation with cytotoxicity.

Materials and methods

Reagents

Taxol was purchased from Sigma Chemicals (St. Louis, Mo.). The synthesis and characterization of the analogs has been described previously [16, 17, 20–25]. Structurally related taxol analogs (designated analogs 1–11) are described in Table 1 and Fig. 1B. All




Fig. 1A,B Structure of taxol analogs. **A** Taxol. Positions of all carbons, rings, and hemispheres are noted. **B** Taxol analogs and arbitrarily assigned numbers

drugs were resuspended in sterile dimethylsulfoxide (DMSO) to a concentration of 20 mM. All drugs were stored at 4 °C and warmed to room temperature prior to use.

Cells

The human ovarian cancer cell lines OVCA 420, OVCA 429 (kindly provided by Dr. Robert Bast, Jr., MD Anderson, Houston) and OC-194 (kindly provided by Dr. Otoniel Martinez-Maza, UCLA) were maintained as monolayer cultures in DMEM/F12 medium supplemented with 5% fetal bovine serum. RAW 264.7 cells were obtained from and maintained according to recommendations from the American Type Culture Collection (Rockville, Md.).

Table 1 Structurally related taxol analogs (*N* nortaxol, *T* taxol)

No.	Compound	Basic ring structure	Position modified	Reference
1	4-Deacetyl-5-hydroxy-20-acetyl-A-nortaxol	N	C-1 ^a , C-5	20
2	10-Deacetylbaecatin	T	C-10 ^a , C-13 ^b	21
3	16-Demethyl-1-keto-A-nortaxol	N	C-1 ^a	21
4	2- <i>S</i> -Methylxanthyl-1-benzoyltaxol	T	C-1 ^a , C-2 ^a	22
5	1-Benzoyl-2-debenzoyloxytaxol	T	C-1 ^a , C-2 ^b	22
6	15,16-Dihydro-A-nortaxol	N	C-1 ^a	20
7	7-Deoxytaxol	T	C-7 ^b	23
8	2-(<i>m</i> -Cyanbenzoyl)-A-nortaxol	N	C-1 ^a , C-2 ^b	21
9	7-Epitaxol	T	C-7 ^c	23
10	10-Deacetyltaxol	T	C-10 ^a	20
11	Taxotere	T	C-10 ^a , C-13 ^a	24,25
12	Taxol	T		16

^a Substitution^b Deletion^c Steric change

RNA analysis

Proliferating, subconfluent cells, were exposed to the analogs at a concentration of 20 μ M, a concentration previously shown to maximally induce IL-8 expression [9]. After 6 h, total RNA was isolated using guanidium isothiocyanate/cesium chloride ultracentrifugation. Northern analysis was performed on 5 μ g total RNA per sample separated on 1% agarose/formaldehyde gels. Blots were prehybridized, hybridized and washed as described previously [9]. All experiments were performed at least twice. Representative Northern blots are shown. Densitometry was performed using the NIH Image 1.49 software for Macintosh. Where appropriate data are expressed as fold induction for each analog compared to the untreated control.

Cytotoxicity assays

Cells, 5000 per well, were plated in 96-well microtiter plates. After adhering overnight, cells were exposed to 20 μ M taxol or taxol analog for 72 h. Cytotoxicity was determined using the MTT metabolic assay [26]. MTT (Sigma) was added to a final concentration of 50 μ g/ml during the last 4 h of incubation. Formazan product was solubilized in 100% DMSO and the optical density measured at 595 nm. The results are expressed as percent survival relative to control cells after subtraction of the background values. Assays were performed in triplicate. All experiments were performed at least twice. Representative data are shown.

Results

Taxol (Fig. 1A) transcriptionally activates IL-8 gene expression and induces IL-8 secretion in the ovarian cancer cell line OVCA 420 [9]. We made chemical modifications to the taxol molecule to determine which region of the molecular skeleton is important for IL-8 gene induction (analog 1–11; Table 1, Fig. 1B). OVCA 420 cells were treated with these structurally related taxol analogs and the resultant changes in IL-8 gene expression were assessed by Northern analysis (Fig. 2A). A low level of constitutive IL-8 mRNA was detected in unstimulated cells when the blot was overexposed (lane 1). IL-8 mRNA was not upregulated by exposure to DMSO (Fig. 2A, lane 2). Analogs 1 and 2 did not induce IL-8 mRNA expression (lanes 3 and 4). Analogs 4, 5 and




Fig. 2A,B Taxol analogs induce cytokine gene expression in OVCA 420 cells. **A** OVCA 420 cells were treated with 20 μ M taxol analogs for 6 h. Total RNA was isolated as described in Materials and methods with 5 μ g per lane separated on 1% agarose/formaldehyde gels. Blots were probed sequentially for IL-8, GRO, IL-1 β and β -actin. Ethidium bromide-stained ribosomal RNA is shown for loading comparison (U untreated cells, D DMSO-treated cells). Analog numbers refer to those in Table 1 and Fig. 1. **B** Graphical representation of densitometry of Northern blot. Data are expressed as fold induction for each analog compared with the untreated control (Filled bars IL-8, hatched bars GRO, open bars IL-1 β)

6 (lanes 6–8) dramatically upregulated IL-8 mRNA expression compared to taxotere (analog 11, lane 13) and taxol (analog 12, lane 14). When compared with untreated control cells, the induction of IL-8 by taxol was approximately 8-fold, while IL-8 mRNA induced by analogs 4, 5 and 6 was 27-, 23- and >30-fold, respectively (Fig. 2B). The remaining analogs (analogs 3, 7–10) induced levels of IL-8 mRNA comparable to that induced by taxol, ranging from 2 to 7-fold over the untreated control (Fig. 2B).

We further screened the taxol analogs 1–11 for the induction of other cytokine genes to determine if the response was specific only for IL-8. We probed the Northern blots for the related chemokine GRO, and for a non-related cytokine, IL-1 β . In a pattern similar to that seen for IL-8, analogs 4, 5 and 6 were more effective than taxol at inducing GRO (Fig. 2A). In agreement with previous results [9], taxol did not induce IL-1 β mRNA. However, analogs 4, 5 and 6 did induce a small increase (2-fold) in IL-1 β mRNA expression. Taxol and several analogs also affected the basal expression of β -actin (Fig. 2A).

We extended the studies to include additional ovarian cancer cell lines (Fig. 3A). OVCA 429 cells, previously shown to express IL-8 mRNA in response to taxol [9], also were responsive to analogs 4 and 5 (Fig. 3A) with a marked enhancement of IL-8 gene induction (approximately 15-fold over control DMSO-treated cells). Exposure to the other analogs induced IL-8 mRNA expression comparable to that seen with taxol (approximately 2–3-fold over controls). An exception was analog 8 which induced IL-8 mRNA approximately 7-fold over its induction in control DMSO-treated cells. OC-194 cells, which do not express IL-8 in response to taxol, showed marginal gene induction following exposure to analogs 4 and 5 (data not shown) and analog 6 (Fig. 3B). These cells can express IL-8 in response to IL-1 β stimulation [27]. We first primed OC-194 cells with 0.5 ng/ml IL-1 β and then exposed them to drug in the absence of additional cosignals, and assessed IL-8 mRNA levels by Northern analysis. Figure 3B shows that following such treatment there was an enhanced induction of IL-8 in cells treated with analog but not in cells treated with taxol (Fig. 3B). OC-194 cells exposed to IL-1 β and then analogs 1, 2, 3, 9, 10 and 11 did not show enhanced induction of IL-8 mRNA (data not shown).

We further analyzed the ability of the structural analogs 1–11 to induce TNF α expression from the murine macrophage cell line RAW 264.7 (Fig. 3C). In contrast to the studies with the human ovarian OVCA 420 cell line, TNF α expression was induced most prominently by taxol, analog 7 and analog 9 (Fig. 3C, lanes 14, 9 and 11, respectively). Analogs 4, 5 and 6 induced only marginal TNF α gene expression. Stimulation by LPS was used as a positive control (Fig. 3C, lane 2).

Finally, we attempted to correlate IL-8 gene induction with cytotoxicity. OVCA 420, OVCA 429 and OC-194 cells were continuously exposed to 20 μ M taxol or taxol analogs for 72 h and cytotoxicity assessed by the




Fig. 3A–C Analog-induced IL-8 gene expression in OVCA 429 and OC-194 cells. **A** OVCA 429 cells were exposed to 20 μ M taxol or analogs for 5 h. **B** OC-194 cells were exposed to 0.5 ng/ml IL-1 β for 10 min at 4 $^{\circ}$ C prior to a 5-h exposure to 20 μ M taxol or analog 6 in the absence IL-1 β . **C** TNF α expression induced in murine RAW 264.7 cells following exposure to 20 μ M analogs or LPS (L) 10 ng/ml for 4 h. GAPDH expression is shown for loading comparison. Ethidium bromide-stained gels showing ribosomal RNA are shown for loading comparison in **A** and **B**

MTT assay (Fig. 4A). The cytotoxicity induced by the analogs mirrored the pattern of IL-8 gene induction in all cell lines. Treatment with analog 1 failed to significantly induce cytotoxicity, while exposure to analog 2 resulted in approximately 30% cytotoxicity. The analogs 3, 7, 8, 9, 10, 11 induced cytotoxicity comparable to that seen with taxol. These analogs significantly inhibited cell survival by approximately 50–70%. Analogs 4, 5 and 6 exhibited the greatest cellular cytotoxicity, approximately 85–98%. Similar results were obtained when the cells were exposed to taxol or taxol analogs for 3 h and then maintained in the absence of drug for 72 h (data not shown).

Figure 4B shows the correlation between cytotoxicity and IL-8 gene induction. Analogs that demonstrated the highest cytotoxicity (poorest cell survival) produced the




Fig. 4A,B Analog-induced cytotoxicity and correlation with IL-8 gene induction. **A** Cells were exposed to 20 μ M taxol or analog for 72 h and cytotoxicity determined using the MTT assay. **A** representative of three experiments is shown (open bars OC-194, slashed bars OVCA 420, solid bars OVCA 429). **B** Correlation between IL-8 gene induction (fold induction, solid bars) and cytotoxicity (percent survival, open bars) for OVCA 420 cells. Data are shown only for analogs that induce IL-8 gene expression

highest gene induction (analogs 4, 5 and 6). Analogs (analogs 3 and 8) modified in the same southern hemisphere were more cytotoxic than those that were modified in the northern hemisphere including taxol and taxotere.

Discussion

The in vivo efficacy of taxol is greater than that of other antimetabolic agents, suggesting additional mechanisms of action. As taxol has been shown to transcriptionally activate a number of genes including IL-8 and *GADD153* [9, 10], we hypothesized that taxol could alter the expression of factors that either directly or indirectly modulate tumor growth. While the signaling pathways responsible for taxol-induced transcriptional activation are under much investigation, little is known about the structural elements of the taxol molecule itself that are

required for optimum gene induction. To address this question we tested a series of structurally related taxol analogs modified at the core structure and/or functional group disposition and assessed changes in IL-8 gene expression in two human ovarian cancer cell lines.

Our results indicate that the southern hemisphere of the taxol molecule, C-1 to C-4, plays a dominant role in both IL-8 gene induction and cytotoxicity. In particular, modification at C-1 and C-2 atoms, as in analogs 4, 5 and 6, enhanced the ability to induce IL-8 gene expression (Figs. 2A and 3A), IL-8 protein secretion (data not shown) and cytotoxicity (Fig. 4). In analog 4, 2-*S*-methylxanthyl-1-benzoyltaxol, the C-1 hydroxyl group is replaced by a benzoate ester and the C-2 benzoate ester is replaced by an *S*-methyl xanthate functional group. In analog 5, 1-benzoyl-2-debenzoyloxytaxol, the C-1 hydroxyl group is protected as a benzoate group and the C-2 benzoate group has been reduced to a methylene group [22]. These modifications in the southern hemisphere of the molecule are functional group transformations which cause a loss in the polarity and increase the hydrophobicity in this region by removing the C-1 hydroxyl. It is thus possible that the loss in hydrophilicity and the gain in hydrophobicity in the southern hemisphere of the taxane molecule, specifically at the C-1 and C-2 positions, enhances both IL-8 gene induction and cytotoxicity in OVCA 420 and OVCA 429 cells.

In analog 6, dihydro-A-nortaxol, the taxane ring skeleton is modified by a contraction from 6:8 AB ring fusion with the loss of C-1 hydroxyl group (loss of hydrophilicity) and the gain of a pendant isopropyl group (gain in hydrophobicity). It is noteworthy that despite a change in the ring skeleton of analog 6 as compared to taxol, the overall conformation of both these molecules remains the same [21]. Analogs 3 and 8 also contain the same modified skeleton as in analog 6, but in these analogs the C-1 carbon is attached to an sp^2 carbon, the effect of which is not clearly understood. The addition of a cyano group at the meta position of the C-2 aryl ring in analog 8, 2-(*m*-cyanbenzoyl)-A-nortaxol, reduced the IL-8-inductive capacity of analog 6. Movement of this group to other positions on the 2-benzoyl ring also resulted in a loss of IL-8 induction (data not shown), inferring specificity of this region for gene induction. This region is also important in cytotoxicity as analogs 3 and 8 were less effective than analog 6 at cell killing.

In parallel to IL-8 gene induction, the cytotoxicity assays show similar trends, with analogs 4, 5 and 6 being the most effective (Fig. 4B). Previously, these analogs have been reported to be less effective than taxol at inducing cytotoxicity against P-388 cells and several human cancer cell lines with ED_{50} values being approximately 10–50-fold higher than that of taxol [21, 22]. In this study, we showed that these analogs were more effective than taxol at cell killing when cells were exposed to a single concentration that induced IL-8 gene expression. While the results reported here do not reflect the ED_{50} values for these analogs against the cell

lines used in this study, our results are in agreement with those of earlier studies confirming the importance of the C-2 benzoyl group for cytotoxicity [21, 22].

In the case of analog 1, 4-deacetyl-5-hydroxy-20-acetyl-A-nortaxol, not only is the basic ring skeleton modified as in analog 6, but also the oxetane ring (ring D) is opened. When compared with analog 6, it appears that the overall conformation of the taxol molecule is also required for IL-8 induction. It is known that opening the oxetane ring causes the molecule to lose its rigid conformation and this results in a loss of bioactivity as shown previously [16, 19, 20, 28].

Both cytotoxicity and IL-8 induction in human ovarian cancer cells appear sensitive to modifications in the southern hemisphere of the taxane molecule. This is in contrast to studies analyzing TNF α production in murine macrophages where changes in the northern hemisphere, specifically in the C-7 carbon substituent on the C-ring, have profound effects on the TNF α gene response. Burkhart et al. [18] have reported that the induction of TNF α by C-7 acetyl taxol, where the C-7 hydroxy group is protected as an ester, is 70–80% less than that induced by taxol. In agreement with these observations, we found that changes in the northern hemisphere, specifically a stereochemical change in the C-7 hydroxyl group (analog 9, 7-epitaxol), resulted in a diminution of TNF α expression from murine macrophages compared to taxol. Interestingly, we found that deletion of the C-7 hydroxyl group (analog 7, 7-deoxytaxol) induced TNF α mRNA.

Of interest was the finding that in contrast to taxol, the analogs that markedly induced IL-8 (analog 4, 5 and 6) were capable of augmenting IL-8 expression in IL-1-primed cells (Fig. 3B). While this observation suggests that the analogs and taxol utilize separate pathways for inducing IL-8 gene expression in taxol-unresponsive cell lines (those that fail to induce IL-8 in response to taxol), it does not negate the possibility of a common mechanism in taxol-responsive cell lines (those that do induce IL-8 in response to taxol). We have determined that the induction of gene expression follows similar kinetics in cells exposed to taxol or taxol analogs. However, while the transcriptional response to taxol is transient, the analogs cause sustained transcriptional activation (J.M.W. and J.S.H., unpublished observation) resulting in the increased mRNA levels seen 6 h after exposure. These data support the utilization of a common signal pathway by both taxol and analogs to elicit the response, possibly through the *c-raf*-1/MAP kinase pathway or the activation of the transcription factors AP-1 and NF- κ B [15, 29], but an additional unknown pathway may be used by the analogs for maintenance of IL-8 gene expression.

Although the importance of IL-8 induction in the pathogenesis of ovarian cancer remains unclear, we observed a direct correlation between IL-8 induction and cytotoxicity. The analogs that were most potent at inducing IL-8 gene expression were also the most cytotoxic (Fig. 4B). IL-8-neutralizing antibodies failed to block

taxol or analog-induced cytotoxicity (data not shown) indicating that IL-8 does not mediate taxol-induced cytotoxicity. Furthermore cells that failed to express IL-8 mRNA (Fig. 3B) were as sensitive to the cytotoxic effects of taxol or analogs (Fig. 4) as those cells that did express IL-8 mRNA (Figs. 2 and 3A). However, there are several important biological functions of this chemokine that could be of significance to the pathology of ovarian cancer and the *in vivo* effectiveness of taxol. As a potent chemoattractant [1], taxol-induced IL-8 may enhance the infiltrate of inflammatory cells into the tumor microenvironment. Patients with ovarian cancers that present with increased percentages of inflammatory cells have a better prognosis than those with few inflammatory cells [30]. IL-8 also has the potential to modulate cell adhesion molecules and cell adhesive properties of both inflammatory and presumably tumor cells, ultimately affecting cell metastasis [2]. It is unclear whether this would have beneficial or detrimental effects for the patient. In a murine model of melanoma, the expression of IL-8 directly correlates with the ability of the tumor to metastasize [4, 5], possibly through enhanced angiogenesis induced by IL-8 [6, 7]. Finally, it is unlikely that IL-8 is the only cytokine or protein induced by taxol that could modulate the tumor microenvironment. Although taxol induces IL-8 in the human colon cancer cell line T84 [9], it is unclear whether this response is unique to these cells. Future studies aimed at identifying other taxol-induced factors will be aided by understanding which structural regions of taxol contribute to the various biological functions. This knowledge may improve understanding of taxol's therapeutic efficacy *in vivo* and may lead to enhanced therapeutics.

We assessed IL-8 gene induction and cytotoxicity of a limited number of taxol analogs. We primarily restricted our study to the investigation of analogs with modifications on the ring skeleton, although we did include two analogs that were modified on the C-13 sidechain, taxotere (analog 11) and 10-deacetylbaicatin (analog 2). Other studies have shown that modifications to the C-13 sidechain can increase drug solubility [31–33] or can increase or decrease cytotoxicity [18, 28, 34]. The effects of other analogs modified at sidechain positions 3' or 2' on IL-8 gene induction are unknown but would be worthy of investigation. We did find that taxotere (analog 11) could induce IL-8 expression but to a lesser extent than taxol. In our system, taxotere and taxol showed comparable cytotoxicity. In conclusion, we have demonstrated that changes in the southern hemisphere of the taxol molecular structure have prominent effects on IL-8 gene induction in two human ovarian cancer cell lines. This induction of IL-8 mRNA is in parallel with the observed cytotoxicities for these analogs and may thus be of significant clinical importance.

Acknowledgements We thank Dr. Tom Hamilton (Cleveland Clinic, Cleveland, Ohio) for the mouse TNF α and GAPDH cDNA probes, and John Morris for technical assistance. This work was funded in part by NIH grants # AI26774 (J.S.H.) and CA 55131

(D.G.I.K.). J.M.W. was a recipient of an NIH postdoctoral fellowship (CA63794).

References

1. Baggiolini M, Dewald B, Moser B (1994) Interleukin-8 and related chemotactic cytokines – CXC and CC chemokines. *Adv Immunol* 55: 97
2. Braun RK, Franchini H, Erard F, Rihs S, DeVries IJ, Blaser K, Hansel TT, Walker C (1993) Human peripheral blood eosinophils produce and release IL-8 on stimulation with calcium ionophore. *Eur J Immunol* 23: 956
3. Schuerer-Maly C-C, Eckmann L, Kagnoff MF, Falco MT, Maly FE (1994) Colonic epithelial cell lines as a source of interleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. *Immunology* 81: 85
4. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ (1994) Expression of IL-8 correlates with the metastatic potential of human melanoma cells in nude mice. *Cancer Res* 54: 3242
5. Singh RK, Gutman M, Reich R, Bar-Eli M (1995) Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of IL-8. *Cancer Res* 55: 3669
6. Kock AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM (1992) IL-8 as a macrophage-derived mediator of angiogenesis. *Science* 258: 1798
7. Smith DR, Polverini RJ, Kunkel SL, Orringer MB, Whyte RL, Burdick MD, Wilke CA, Strieter RM (1994) Inhibition of IL-8 attenuates angiogenesis in bronchogenic carcinoma. *J Exp Med* 179: 1409
8. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med* 334: 1
9. Lee L-F, Schuerer-Maly C-C, Lofquist AK, van Haaften-Day C, Ting JP-Y, White CM, Martin BK, Haskill JS (1996) Taxol-dependent transcriptional activation of IL-8 expression in human ovarian cancer. *Cancer Res* 56: 1303
10. Gately DP, Sharma A, Christen RD, Howell SB (1996) Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of *GADD153*. *Br J Cancer* 73: 18
11. Vogel SN, Carboni JM, Manthey CL (1995) Paclitaxel, a mimetic of bacterial lipopolysaccharide (LPS) in murine macrophages. In: Georg GI, Chen TT, Ojima I, Vyas DM (eds) *Taxane anticancer agents. Basic science and current status*. (ACS Symposium series 583) American Chemical Society Press, Washington, DC p 162
12. Ding AH, Porteu F, Sanchez E, Nathan CF (1990) Shared actions of endotoxin and taxol on TNF receptors and TNF release. *Science* 248: 370
13. O'Brien JM Jr, Wewers MD, Moore SA, Allen JN (1995) Taxol and colchicine increase LPS-induced pro-IL-1 β production but do not increase IL-1 β secretion. *J Immunol* 154: 4113
14. Manié S, Schmid-Alliana A, Kubar J, Ferrua B, Rossi B (1993) Disruption of microtubule network in human monocytes induces expression of interleukin-1 but not that of interleukin-6 nor tumor necrosis factor- α . *J Biol Chem* 268: 13675
15. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L (1995) Taxol induction of p21^{WAF1} and p53 requires c-raf-1. *Cancer Res* 55: 4623
16. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from *Taxus brevifolia*. *J Am Chem Soc* 93: 2325
17. Kingston DGI, Molinero AA, Rimoldi JM (1993) The taxane diterpenoids. In: Herz W, Kirby GW, Moore RE, Steglich W, Tamm C (eds) *Progress in the chemistry of organic natural products*, vol 61. Springer-Verlag, New York, pp 1–206
18. Burkhart CA, Berman JW, Swindell CS, Horowitz SB (1994) Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor- α and cytotoxicity. *Cancer Res* 54: 5779
19. Parness J, Kingston DGI, Powell RG, Harracksingh C, Horowitz SB (1982) Structure-activity study of cytotoxicity and microtubule assembly *in vitro* by taxol and related taxanes. *Biochem Biophys Res Commun* 105: 1082
20. Samaranayake G, Magri NF, Jitrangsi C, Kingston DGI (1991) Modified taxols. 5. Reaction of taxol with electrophilic reagents and preparation of a rearranged taxol derivative with tubulin-assembly activity. *J Org Chem* 56: 5114
21. Chordia MD, Kingston DGI, Hamel E, Lin CM (1997) Synthesis and biological activity of A-norpaclitaxel analogs. *Bioorg Med Chem* 5: 941
22. Chaudhary AG, Chordia MD, Kingston DGI (1995) A novel benzoyl group migration: synthesis and biological evaluation of 1-benzoyl-2-des(benzoyloxy)paclitaxel. *J Org Chem* 60: 3260
23. Chaudhary AG, Rimoldi JM, Kingston DGI (1993) Modified taxols. 10. Preparation of 7-deoxytaxol, a highly bioactive taxol derivative, and interconversion of taxol and 7-epi-taxol. *J Org Chem* 58: 3298
24. Mangatal L, Adeline MT, Guénard D, Guéritte-Voegelein F, Potier P (1989) Application of the vicinal hydroxyamination reaction and asymmetric induction to the hemisynthesis of taxol and analogs. *Tetrahedron* 45: 4177
25. Grover S, Rimoldi JM, Molinero AA, Chaudhary AG, Kingston DGI, Hamel E (1995) Differential effects of paclitaxel (taxol) analogs modified at positions C-2, C-7 and C-3' on tubulin polymerization and polymer stabilization: identification of a hyperactive paclitaxel derivative. *Biochemistry* 34: 3927
26. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J Immunol Methods* 83: 55
27. Watson JM, Lofquist AK, Rinehart CA, Olsen JC, Makarov SS, Kaufman DG, Haskill JS (1995) The intracellular IL-1 receptor antagonist alters IL-1 inducible gene expression without blocking exogenous signaling by IL-1 β . *J Immunol* 155: 4467
28. Kingston DGI, Samaranayake G, Ivey GA (1990) The chemistry of taxol, a clinically useful anticancer agent. *J Nat Prod* 53: 1
29. Lee L-F, Haskill JS, Mukaida N, Matsushima K, Ting JP-Y (1997) Identification of tumor-specific taxol responsive regulatory elements (TRRE) in the IL-8 promoter. *Mol Cell Biol* 17: 5097
30. Haskill S, Becker S, Fowler W, Walton L (1982) Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material. *Br J Cancer* 45: 728
31. Magri NF, Kingston DGI (1988) Modified taxols. 4. Synthesis and biological activity of taxols modified in the side chain. *J Natl Prod* 51: 298
32. Deutsch HM, Glinski JA, Hernandez M, Haugwitz RD, Narayanan VL, Suffness M, Zalkow LH (1989) Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. *J Med Chem* 32: 788
33. Mathew AE, Majillano MR, Nath JP, Hines RH, Stella VJ (1992) Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. *J Med Chem* 35: 145
34. Huizing MT, Sewberath Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CHN, Vermorken JB, Pinedo HM, Beijnen JH (1995) Taxanes: a new class of antitumor agents. *Cancer Invest* 13: 381